PEPTIDE COMPARISON

CJC-1295 vs Sermorelin

A long-acting GHRH analog compared with a shorter historical GHRH fragment.

QUICK ANSWER

CJC-1295 vs Sermorelin: the main difference.

CJC-1295 is designed for longer exposure, while sermorelin is a shorter GHRH fragment with a longer clinical history. Those differences do not establish superior health outcomes for either product.

Decision field	CJC-1295	Sermorelin
Human research	Small hormone-response studies	Historical diagnostics and deficiency research
Mechanism	Long-acting GHRH analog	GHRH(1-29) analog
Product identity	DAC and non-DAC products may be conflated	Historical products and current compounded products differ
FDA status	Not approved	No current approved product identified
Evidence confidence	Low for outcomes	Low for modern wellness claims

SOURCES

CJC-1295 vs Sermorelin sources.

Human trial / 2006Prolonged stimulation of growth hormone and IGF-1 by CJC-1295PubMed WADA / 20262026 Prohibited ListWorld Anti-Doping Agency FDA / 2026Drugs@FDA databaseU.S. FDA

CJC-1295 vs Sermorelin: the main difference.

CJC-1295 vs Sermorelin sources.

Questions related to CJC-1295 vs Sermorelin.

Compare the next decision.